Chemomab Therapeutics Ltd. (CMMB): Total Liabilities
$1.48M
As of 2025-12-31
-40.0%
3-year compound annual growth
-2.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.48M | -56.9% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $3.43M | -33.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $5.15M | -24.6% | 2025-04-04, Balance as of period end |
| 2022-12-31 | $6.84M | +136.9% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $2.89M | +72.5% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $1.67M | n/c | 2022-03-30, Balance as of period end |
| 2019-12-31 | $4.85M | +63.9% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $2.96M | n/a | 2020-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $123.69M | +8.4% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $6.11M | -33.7% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $20.23M | +275.8% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Biovie Inc. (BIVI) | 2026-06-30 | $3.98M | +56.1% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $5.03M | +115.6% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
Compare CMMB, CYDY, ACTU, CALC side by side · Screen every company in Pharmaceutical Preparations ↗